sinopharm品牌介绍

浏览量：2509

sinopharm

品牌简介

国药集团作为国家创新型企业，依托强大的研发实力，不断在关键领域和前沿领域取得创新成果，保障人民群众健康。其中，国家一类新药肠道病毒71型灭活疫苗（EV71灭活疫苗）的研发生产，有效降低我国儿童手足口病的发病率；脊髓灰质炎灭活疫苗（sIPV）的研发上市，确保了我国脊髓灰质炎免疫规划战略的实施；二价脊髓灰质炎减毒活疫苗（bOPV）通过世界卫生组织预认证，在全球消灭脊髓灰质炎行动中发挥了重要作用；乙型脑炎减毒活疫苗作为我国首个通过世界卫生组织预认证的疫苗产品，纳入联合国机构采购，整个世界因此受益。

Sinopharm Group, as a national innovative enterprise, relies on strong research and development strength, and constantly achieves innovation results in key fields and frontier fields to protect the health of the people. Among them, the development and production of the national new Class A enterovirus 71 inactivated vaccine (EV71 inactivated vaccine) has effectively reduced the incidence of hand-foot-mouth disease in children in China; The development and marketing of poliomyelitis inactivated vaccine (sIPV) ensured the implementation of poliomyelitis immunization planning strategy in China; The live attenuated bivalent poliomyelitis vaccine (bOPV) has been pre-certified by the World Health Organization (WHO) and has played an important role in the global polio eradication Initiative. Japanese encephalitis live attenuated vaccine, as the first vaccine product in China to pass the pre-certification of the World Health Organization, was included in the procurement of United Nations agencies, and the whole world benefited from it